Grigeo (GRG1L) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
21 Nov, 2025Executive summary
Revenue rose by EUR 14.9 million (9%) year-over-year to EUR 173.0 million for the 9 months of 2025.
EBITDA increased by EUR 1.0 million (4%) to EUR 24.7 million, while profit before tax (EBT) decreased by EUR 1.2 million (7%) to EUR 15.4 million.
Financial highlights
Net profit for the period was EUR 13.9 million, down slightly from EUR 14.1 million year-over-year.
Gross margin declined to 21.0% from 22.6% year-over-year.
Earnings per share were EUR 0.105, compared to EUR 0.109 in the prior year.
Operating cash flow increased to EUR 26.7 million from EUR 14.4 million year-over-year.
Outlook and guidance
Management notes ongoing uncertainty due to the war in Ukraine, particularly regarding the Ukrainian subsidiary Mena Pak AT.
No significant changes in risk management or financial risk factors during 2025.
Latest events from Grigeo
- Revenue surged 31% but profit margins and net profit declined amid rising costs and legal risks.GRG1L
Q1 2026 - Revenue up 16% YoY, but profit and margins fell; expansion and legal risks remain.GRG1L
Q4 2025 - Revenue up 12% but profit and margins down; EUR 106m tissue investment planned.GRG1L
Q2 2025 - Revenue up, but profit and margins down; legal and geopolitical risks remain elevated.GRG1L
Q3 2024 - EBITDA and net profit fell despite revenue growth, with margin pressure and legal risks ongoing.GRG1L
Q2 2024 - Revenue up 22% but margins and profit before tax declined amid ongoing legal risks.GRG1L
Q1 2025 - Revenue up 9% but profit down 13% amid margin pressure and legal risks.GRG1L
Q4 2024